Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shenzhen Kangtai Biological Pr (300601 CH)
Watchlist
51
Analysis
Health Care
•
China
Shenzhen Kangtai Biological Products Co., Ltd. operates biological product manufacturing businesses. The Company produces biological vaccines and other vaccine products. Shenzhen Kangtai Biological Products conducts businesses in China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Shanghai Pharmaceuticals Holding
•
10 Nov 2022 09:24
Shanghai Pharmaceuticals (2607.HK)- Low Profitability Is Big Problem; Share Price Would Underperform
Due to VBP, Shanghai Pharmaceuticals will face low margin. Weak COVID vaccine demand/uncertain synergistic effect of cooperation with Yunnan Baiyao...
Xinyao (Criss) Wang
Follow
246 Views
Share
bearish
•
Pfizer Inc
•
09 Nov 2022 09:02
Pfizer Inc (PFE.US) - What if Pfizer Loses the China Market in the Future?
Pfizer’s China business faces challenges due to VBP/NRDL negotiation and potential further deterioration of Sino-US relations. Together with...
Xinyao (Criss) Wang
Follow
168 Views
Share
bearish
•
CanSino Biologics
•
03 Nov 2022 10:35
CanSino Biologics (6185.HK/688185.CH) - Time to Offload; the Rally May Not Last Long
The fake news about China reopen and COVID-19 vaccine business are major driving force for the rally of CanSino’s share price, but such rally would...
Xinyao (Criss) Wang
Follow
186 Views
Share
bearish
•
Chongqing Zhifei Biological Products
•
27 Oct 2022 08:54
Zhifei Biological Products (300122.CH) - More Downside Ahead, with Untenable Logic in HPV Vaccine
Zhifei’s HPV vaccine will face real risk as competing products launch from 2024. The real potential of China HPV vaccine market is much lower than...
Xinyao (Criss) Wang
Follow
171 Views
Share
bullish
•
CanSino Biologics
•
19 Oct 2022 08:51
CanSino Biologics Inc (688185.CH/6185.HK) - Some Positive Progress in Business
Cansino has made positive progress in commercialization and R&D recently. We look forward to the performance of MCV4 in H2. Its valuation in HKEX...
Xinyao (Criss) Wang
Follow
228 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x